means for MASI were highest for those with severe MSS and the lowest for those with mild MSS (means: mild, 6.9 [95% CI, 4.9-8.8]; moderate, 12.4 [95 CI,]; severe, 20.2 [95% CI, 18.6-21.9]).
Interpretability of the Modified Melasma Area and Severity Index (mMASI)
Melasma is a disorder of pigmentation commonly affecting women with darker skin types. 1 Owing to the recalcitrant nature of melasma, more randomized controlled clinical trials of new treatment modalities are needed. These trials require precise categorization of disease severity to select appropriate patients for enrollment and determine response to treatment. The Melasma Area and Severity Index (MASI) is the most common outcome measure used for melasma studies, and was validated 20 years after it was first reported. 2, 3 This validation process eliminated homogeneity as a part of the MASI, resulting in the new modified MASI score (mMASI). 3 Calculation of the mMASI score is performed by rating darkness and area of involvement of 4 areas of the face. These figures are then inserted into an equation, resulting in the final mMASI score (Table) .
Despite the development of the mMASI score, a global severity score is also needed to determine optimal outcomes in clinical trials in melasma. Global scores are commonly used in clinical research studies and are intended to provide a clinically meaningful snapshot of disease severity that is easily understandable to physicians and patients. The melasma severity score (MSS) has been used in large trials as a global score. 4 The MSS has 4 grades of severity (clear, mild, moderate, severe), with clear or mild as ideal outcomes in trials of patients with moderate to severe melasma. 4 This is important to clinicians because treatments that show a significant reduction of moderate to severe melasma to clear or mild melasma are favored by patients. 4 However, the correlation of the mMASI to MSS categories is unknown. We sought to stratify the mMASI into ranges correlating with mild, moderate, and severe melasma so that clinicians can better interpret melasma studies and investigators can identify patients with moderate to severe melasma by correlating MSS categories to mMASI scores.
Methods | Data for 79 patients with melasma were retrospectively reviewed in this study approved by the University of Texas Southwestern Medical Center institutional review board. Melasma for all patients had been scored using the MSS, MASI, and mMASI. The data were analyzed by comparing the results of the MSS scores to the MASI and mMASI to determine if distinct ranges for mild, moderate, and severe melasma existed.
One-way analysis of variance (ANOVA) was used to examine mMASI and MASI by MSS group. Assumptions of ANOVA (equal group variance and normality) were checked. When the ANOVA was significant, the Bonferroni post hoc test was performed. SPSS software (version 21) was used for analyses, and Sigma Plot (version 12.5) was used to produce the figures.
Results | Modified MASI. The MSS groups for mMASI were found to be significantly different (P < .001; partial η 2 = 0.42) (Figure) . All pairwise Bonferroni post hoc tests were significant (P < .001); the means for mMASI were the highest for those with severe MSS and the lowest for those with mild MSS (means: mild, 3.8 [95% CI, 2.7-4.9]; moderate, 6.5 [95% CI, 5.8-7.2]; severe, 8.9 [95% CI, 8.0-9.8]).
MASI. The MSS groups for MASI were also found to be significantly different (P < .001; partial η 2 = 0.60) (Figure) . All pairwise Bonferroni post hoc tests were significant (P < .001); the 
Abbreviation: MASI, Melasma Area and Severity Index. a Scoring system: A, Area of involvement rated 0 to 6: 0 indicates absent; 1, <10%; 2, 10% to 29%; 3, 30% to 49%; 4, 50% to 69%; 5, 70% to 89%; 6, 90% to 100%. D, Darkness rated 0 to 4: 0 indicates absent; 1, slight; 2, mild; 3, marked; 4, severe. b Total mMASI score range is 0 to 24 and calculated by adding scores for 4 areas of the face.
Patient Preferences During Skin Cancer Screening Examination
Although skin cancer screening through total-body skin examination (TBSE) may reduce morbidity or mortality from skin cancer, one potential harm of screening is that the nature of this examination may cause patient embarrassment. Among female patients undergoing colonoscopy and pelvic examinations there is a strong preference for a female physician. 1, 2 To our knowledge, the influence of physician sex on patient attitudes toward skin cancer screening has not been studied in a nonveteran population. 3, 4 Methods | Using an anonymous, cross-sectional survey (determined to be exempt from full board review by the institutional review boards of the University of Pittsburgh, University of Utah, and East Carolina University), adults (≥18 years) undergoing a TBSE at these 3 institutions were surveyed to determine their preferences of screening clinician's sex and degree of disrobement during TBSE. Univariate significance was tested using the t test or the χ 2 test.
Results | Of 483 invited participants, 443 completed some or all of the survey and 82 refused (response rate, 85.5%). Population demographics and preferences for examining clinician's sex are shown ( Table 1) . Eighty-five women (33.7%) and 32 men (16.8%) had a preference for physician sex (P < .001), among whom 84 women (98.8%) and 12 men (37.5%) preferred a female physician (P < .001). Clinician sex preference correlated inversely with patient age (50% of women were <30 years; 24.2% of women were ≥70 years) but not with educational attainment or body mass index. For the TBSE, women were more likely than men to prefer to leave undergarments in place (46.2% vs 39.7%; P = .05) and to not have their genitals examined (31.3% vs 12.5%; P < .001) ( Table 2) . However, women were more likely 
